- Home
- Automated
- List of product information
- IMOVAX POLIO INJECTION [SIN10608P]
IMOVAX POLIO INJECTION [SIN10608P]
Active ingredients: IMOVAX POLIO INJECTION
Last updated 26 October 2025
On this page
Product Info
IMOVAX POLIO INJECTION
[SIN10608P]
Product information
Active Ingredient and Strength | INACTIVATED POLIOMYELITIS VIRUS TYPE 1 (MAHONEY) - 40 D.U./0.5 ML |
Dosage Form | INJECTION |
Manufacturer and Country | SANOFI PASTEUR - FRANCE |
Registration Number | SIN10608P |
Licence Holder | SANOFI-AVENTIS SINGAPORE PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | J07BF03 |
Therapeutic indications
This vaccine is indicated for the prevention of poliomyelitis in infants, children and adults, for primary and booster vaccination.
IMOVAX POLIO must be used according to effective official recommendations.
Posology and method of administration
Posology
From the age of 2 months, 3 successive doses of 0.5 mL of IMOVAX POLIO should be administered at intervals of one or two months, followed by a first booster 12 months after the last dose.
For subsequent boosters, an injection is given every 5 years in children and adolescents and every 10 years in adults.
In countries where a live Oral Poliomyelitis vaccine (trivalent, bivalent or monovalent OPV) is used in the routine immunisation programme, IMOVAX POLIO may be used in association (co-administration) or in sequential use with OPV, in accordance with WHO recommendations and in agreement with the national recommendations in effect.
Method of administration
Administration is performed preferably via the intramuscular (IM) route, or via the subcutaneous (SC) route.
Intramuscular injection will be preferably performed in the antero-lateral side of the thigh in young children and in the deltoid muscle in children, adolescents and adults.
For instructions on use, handling and disposal, see section Special precautions for disposal and other handling – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
Contraindications
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information, or to any vaccine containing the same substances, to neomycin, streptomycin or polymyxin B.
Common transient contraindications to any vaccination: in case of fever or acute illness, it is best to postpone vaccination.